Precigen (STU:I5X) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:I5X Precigen Inc STU:I5X
63 GF Score
Price €4.52
GF Value €5.38
Valuation Modestly Undervalued
! 8 Warning Signs
View Full Analysis

What is Precigen Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

STU:I5X
63GF Score
Precigen Inc STU:I5X
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Precigen (STU:I5X) Overvalued in 2026?

Based on GuruFocus' analysis, Precigen stock appears to be undervalued. The current stock price of €4.52 is trading 16% below its estimated GF Value™ of €5.38. GuruFocus considers Precigen to be Modestly Undervalued.

Key valuation signals for STU:I5X:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: €5.38 vs. price of €4.52 (16% below fair value)
  • GF Score™: 63/100 with 8 warning signs

No single metric tells the full story. See the STU:I5X stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Precigen Business Description

Other Exchanges PGEN:USA
Address 20374 Seneca Meadows Parkway, Germantown, MD, USA, 20876
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
63GF Score

Get the complete analysis for STU:I5X

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.52
Price
€5.38
GF Value